权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

A transformative drug discovery platform for allosteric kinase inhibitors

变构激酶抑制剂的变革性药物发现平台

基本信息

批准号：
10595089
负责人：
Nicholas Mark Levinson
金额：
$ 57.17万
依托单位：
UNIVERSITY OF MINNESOTA
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-03-01 至 2026-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10595089
关键词：
Acceleration Adoption Affinity Basic Science Binding Biochemical Biological Assay Biophysics Biosensor Cancer Patient Cancer cell line Chemicals Classification Clinical Complex Couples Detection Development Disease Dissociation Exons FDA approved Fluorescence Fluorescence Resonance Energy Transfer Industrialization Knowledge Libraries Ligands MET gene Malignant Neoplasms Malignant neoplasm of lung Mediating Minnesota Mission Molecular Conformation Monitor Movement Mutation Oncology Oncoproteins Patients Phosphotransferases Proto-Oncogene Proteins c-myc Reader Receptor Protein-Tyrosine Kinases Regulatory Element Research Resistance Resistance development Site Technology Testing Therapeutic Translating Ubiquitination Universities Validation c-myc Genes crizotinib drug development drug discovery field study follow-up high throughput screening industry partner inhibitor innovation instrumentation kinase inhibitor nanosecond next generation novel novel strategies novel therapeutic intervention novel therapeutics photonics prevent programs resistance mutation scaffold sensor sensor technology small molecule success technology development therapeutic target treatment strategy tumor tumorigenesis

项目摘要

Project Summary The University of Minnesota (UMN) and Photonic Pharma (PP) a Minnesota-based drug discovery start-up, have partnered to optimize, field-test, and deploy at industrial scale, an innovative new approach to developing allosteric kinase inhibitors (AKI). These molecules have high potential as novel cancer therapeutics that circumvent clinical resistance to conventional orthosteric kinase inhibitors (OKI). We have developed high- throughput screening (HTS) technology based on nanosecond fluorescence lifetime (FLT) detection of Förster resonance energy transfer (FRET), that tracks ligand-driven kinase allostery with angstrom precision by monitoring structural changes of the activation loop, the key regulatory element in all kinases. This is the first HTS-amenable technology that accurately resolves allosteric effects of kinase inhibitors, relying on high-quality nanosecond FLT readouts unavailable from conventional fluorescence plate readers (PR). PP have developed a proprietary HTS platform that uses FRET biosensors and a state-of-the-art FLT-PR to detect structural readouts in <2 min for 384-well and <5 min for 1536-well plates. By partnering with PP, we will transform our kinase FRET sensor technology into a broadly applicable drug-discovery platform for identifying AKIs. We propose drug-discovery programs on two different targets to demonstrate broad utility and accelerate large- scale adoption of our technology for drug development. In AIM 1, we identify Aurora A inhibitors that downregulate the undruggable c-Myc oncoprotein by inhibiting the scaffolding interaction of Aurora A with c- Myc. These molecules would represent a novel treatment strategy for the large number of cancer patients with c-Myc-driven tumors. In AIM 2, we identify allosteric inhibitors of the c-MET receptor tyrosine kinase as a novel therapeutic strategy for patients with c-MET-driven lung cancer. These patients invariably develop resistance to current MET inhibitors through acquired mutations in the ATP site, and allosteric inhibitors that bind outside the ATP-site would circumvent this mode of resistance, filling an unmet clinical need. This UMN-PP partnership translates decades of biophysics research by two world-leading experts – Levinson and Thomas – toward drug- discovery by resolving ligand-driven allostery in kinases. This is enabled by the FLT-PR instrumentation and know-how required to implement nanosecond FLT detection in assays that resolve allosteric inhibitors in true HTS mode. This overcomes key drawbacks of conventional kinase inhibitor screens, which detect kinase inhibition or binding without regard to allosteric mechanism. The platform is broadly applicable, as almost all kinases undergo the large-scale allosteric structural changes our technology detects. Success of this project will catalyze adoption of this technology targeting a wide range of biomedically important kinases, as highlighted by Photonic Pharma’s successful partnership with Bristol-Myers Squibb on drug discovery for other high-priority therapeutic targets.

项目总结